ANKTIVA

Growth

nogapendekin alfa inbakicept-pmln

BLAINTRAVESICALSOLUTION
Approved
Apr 2024
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
2

Mechanism of Action

inbakicept-pmln is an IL-15 receptor agonist. IL-15 signals through a heterotrimeric receptor that is composed of the common gamma chain (γc) subunit, the beta chain (βc) subunit, and the IL-15-specific alpha subunit, IL-15 receptor α. IL-15 is trans -presented by the IL-15 receptor α to the shared…

Clinical Trials (2)

NCT07108036Phase 2Not Yet Recruiting

A Study to Assess Anktiva in Patients With Long Covid-19.

Started Oct 2025
20 enrolled
Long COVID
NCT07123727Phase 2Recruiting

A Study to Examine Anktiva for the Treatment of COVID-19.

Started Sep 2025
40 enrolled
Long COVIDLong COVID SyndromeLong Covid 19